Immunoglobulin use in neurology: a practical approach.
Mahima KapoorAnthony KhooMichael P T LunnStephen ReddelAisling S CarrPublished in: Practical neurology (2024)
Human immunoglobulin, delivered either intravenously (IVIg) or subcutaneously, is used to treat a range of immune-mediated neurological disorders. It has a role in acute or subacute inflammatory disease control and as a maintenance therapy in chronic disease management. This review considers mechanisms of IVIg action and the evidence for IVIg in neurological conditions. We use Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as frameworks to demonstrate an approach to IVIg use in acute and chronic dysimmune neurological conditions across two different healthcare systems: the UK and Australia. We highlight the benefits and limitations of IVIg and focus on practical considerations such as informed consent, managing risks and adverse effects, optimal dosing and monitoring response. We use these basic clinical practice principles to discuss the judicious use of an expensive and scarce blood product with international relevance.
Keyphrases
- liver failure
- healthcare
- drug induced
- clinical practice
- respiratory failure
- endothelial cells
- oxidative stress
- aortic dissection
- cerebral ischemia
- stem cells
- induced pluripotent stem cells
- case report
- mesenchymal stem cells
- extracorporeal membrane oxygenation
- climate change
- blood brain barrier
- mechanical ventilation
- cell therapy
- replacement therapy